
|Articles|March 15, 2003
Clinical drug trials may be key to reducing macular edema
Baltimore-Macular edema is the final common pathway for visual loss in many diseases, but so far, available treatments have not been effective in improving visual acuity to 20/20 in a significant percentage of patients, according to Julia A. Haller, MD, who spoke during the Current Concepts in Ophthalmology meeting, sponsored by Johns Hopkins University School of Medicine, here.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Regeneron receives another CRL for its Eylea 8 mg
2
Eli Lilly to acquire Adverum Biotechnologies
3
Anti-VEGF innovations in retinal disease: From molecules to medicine
4
SparingVision doses first patient in NYRVANA clinical trial of SPVN20 for retinitis pigmentosa
5
 
 

















































.png)


